Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYMAKER-U06 Substudy 06E in first-line advanced or metastatic esophageal squamous cell carcinoma
2024-514273-22-00Phase 2Authorised
- Sponsor
- Merck & Co.
- Start
- Sep 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 16
01
Overview
Phase 2, open-label trial of ifinatamab deruxtecan, sacituzumab tirumotecan and pembrolizumab in Esophageal Squamous Cell Carcinoma (ESCC) (4 arms), sponsored by Merck & Co. Primary endpoints: Percentage of participants who experience dose-limiting toxicities during the safety lead-in phase, Percentage of participants who experience an adverse event and 1 more. Planned start Sep 2025; status: authorised.
02
Drugs
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on 2024-514273-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514273-22-00.